Cargando…

Levels of bioactive endogenous lipids and health-related quality of life in Chronic Idiopathic Axonal Polyneuropathy

BACKGROUND: Although neuropathic pain is a significant problem in polyneuropathy, the underlying molecular mechanisms are poorly understood. The endogenous bioactive lipids 2-arachidonoyl-glycerol (2-AG), oleoylethanolamide (OEA), palmitoylethanolamide (PEA), and stearoylethanolamide (SEA) are known...

Descripción completa

Detalles Bibliográficos
Autores principales: Lind, Jonas, Stensson, Niclas, Gerdle, Björn, Ghafouri, Nazdar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Open Academia 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445423/
https://www.ncbi.nlm.nih.gov/pubmed/37621890
http://dx.doi.org/10.48101/ujms.v127.8577
_version_ 1785094168369954816
author Lind, Jonas
Stensson, Niclas
Gerdle, Björn
Ghafouri, Nazdar
author_facet Lind, Jonas
Stensson, Niclas
Gerdle, Björn
Ghafouri, Nazdar
author_sort Lind, Jonas
collection PubMed
description BACKGROUND: Although neuropathic pain is a significant problem in polyneuropathy, the underlying molecular mechanisms are poorly understood. The endogenous bioactive lipids 2-arachidonoyl-glycerol (2-AG), oleoylethanolamide (OEA), palmitoylethanolamide (PEA), and stearoylethanolamide (SEA) are known to influence pain and inflammation in the peripheral nervous system. The aim of this study was to explore the plasma levels of endocannabinoids and related lipids and health-related quality of life in patients with polyneuropathy with and without pain. METHODS: Patients (n = 48) with Chronic Idiopathic Axonal Neuropathy were included. Clinical data were retrieved from medical files. All patients filled out the SF-36 and EQ-5D questionnaires. In addition, blood samples were analyzed for 2-AG, OEA, PEA, and SEA. RESULTS: Neuropathic pain was reported in 21 of the patients. There were significantly lower levels of 2-AG in patients with neuropathic pain (P = 0.03), but there were no significant differences in OEA (P = 0.61), PEA (P = 0.95), or SEA (P = 0.97) levels. The patients reporting pain in the hands had significantly lower SEA levels, 10.0 versus 15.0 (P = 0.03). The levels of 2-AG were significantly higher among patients reporting paresthesia in their feet (80.1 vs. 56.3; P = 0.02). Levels of PEA, SEA, and 2-AG were decreased in patients with loss of vibration. PEA and SEA were decreased in patients with loss of pain and temperature, and SEA decreased in patients with loss of sense of touch. However, the differences in the levels of bioactive endogenous lipids were not statistically significant when corrected for multiple comparisons. CONCLUSION: Alterations of 2-AG levels between polyneuropathy patients with and without neurogenic pain indicate that it could play an essential role. Further studies are warranted.
format Online
Article
Text
id pubmed-10445423
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Open Academia
record_format MEDLINE/PubMed
spelling pubmed-104454232023-08-24 Levels of bioactive endogenous lipids and health-related quality of life in Chronic Idiopathic Axonal Polyneuropathy Lind, Jonas Stensson, Niclas Gerdle, Björn Ghafouri, Nazdar Ups J Med Sci Original Article BACKGROUND: Although neuropathic pain is a significant problem in polyneuropathy, the underlying molecular mechanisms are poorly understood. The endogenous bioactive lipids 2-arachidonoyl-glycerol (2-AG), oleoylethanolamide (OEA), palmitoylethanolamide (PEA), and stearoylethanolamide (SEA) are known to influence pain and inflammation in the peripheral nervous system. The aim of this study was to explore the plasma levels of endocannabinoids and related lipids and health-related quality of life in patients with polyneuropathy with and without pain. METHODS: Patients (n = 48) with Chronic Idiopathic Axonal Neuropathy were included. Clinical data were retrieved from medical files. All patients filled out the SF-36 and EQ-5D questionnaires. In addition, blood samples were analyzed for 2-AG, OEA, PEA, and SEA. RESULTS: Neuropathic pain was reported in 21 of the patients. There were significantly lower levels of 2-AG in patients with neuropathic pain (P = 0.03), but there were no significant differences in OEA (P = 0.61), PEA (P = 0.95), or SEA (P = 0.97) levels. The patients reporting pain in the hands had significantly lower SEA levels, 10.0 versus 15.0 (P = 0.03). The levels of 2-AG were significantly higher among patients reporting paresthesia in their feet (80.1 vs. 56.3; P = 0.02). Levels of PEA, SEA, and 2-AG were decreased in patients with loss of vibration. PEA and SEA were decreased in patients with loss of pain and temperature, and SEA decreased in patients with loss of sense of touch. However, the differences in the levels of bioactive endogenous lipids were not statistically significant when corrected for multiple comparisons. CONCLUSION: Alterations of 2-AG levels between polyneuropathy patients with and without neurogenic pain indicate that it could play an essential role. Further studies are warranted. Open Academia 2022-05-30 /pmc/articles/PMC10445423/ /pubmed/37621890 http://dx.doi.org/10.48101/ujms.v127.8577 Text en © 2022 The Author(s). Published by Upsala Medical Society. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Lind, Jonas
Stensson, Niclas
Gerdle, Björn
Ghafouri, Nazdar
Levels of bioactive endogenous lipids and health-related quality of life in Chronic Idiopathic Axonal Polyneuropathy
title Levels of bioactive endogenous lipids and health-related quality of life in Chronic Idiopathic Axonal Polyneuropathy
title_full Levels of bioactive endogenous lipids and health-related quality of life in Chronic Idiopathic Axonal Polyneuropathy
title_fullStr Levels of bioactive endogenous lipids and health-related quality of life in Chronic Idiopathic Axonal Polyneuropathy
title_full_unstemmed Levels of bioactive endogenous lipids and health-related quality of life in Chronic Idiopathic Axonal Polyneuropathy
title_short Levels of bioactive endogenous lipids and health-related quality of life in Chronic Idiopathic Axonal Polyneuropathy
title_sort levels of bioactive endogenous lipids and health-related quality of life in chronic idiopathic axonal polyneuropathy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445423/
https://www.ncbi.nlm.nih.gov/pubmed/37621890
http://dx.doi.org/10.48101/ujms.v127.8577
work_keys_str_mv AT lindjonas levelsofbioactiveendogenouslipidsandhealthrelatedqualityoflifeinchronicidiopathicaxonalpolyneuropathy
AT stenssonniclas levelsofbioactiveendogenouslipidsandhealthrelatedqualityoflifeinchronicidiopathicaxonalpolyneuropathy
AT gerdlebjorn levelsofbioactiveendogenouslipidsandhealthrelatedqualityoflifeinchronicidiopathicaxonalpolyneuropathy
AT ghafourinazdar levelsofbioactiveendogenouslipidsandhealthrelatedqualityoflifeinchronicidiopathicaxonalpolyneuropathy